CIK 0001857044 · Non-accelerated filer<br>Smaller reporting company
Indaptus Therapeutics, Inc.
Sign in to watch- Ticker
- INDP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 863158720
- Phone
- (646) 427-2727
- Business address
- 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK, NY, 10019
- Former names
- Intec Parent Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-25 | Hayes William B Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2023-05-25 | Karah Hila Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2023-05-25 | Gilbert Mark John Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2023-05-25 | Pomerantz Roger Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-05-25 | MADDALUNA ANTHONY J Director | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2023-02-13 | Martell Robert Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-01-18 | Linscott Walt Addison Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2023-01-18 | Meckler Jeffrey A CEO and Director | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2023-01-18 | Sassi Nir Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2023-01-18 | Newman Michael James CSO and Director | Grant or award · Stock Option (Right to Buy) | +43,250 | 43,250 | ||
| 2022-12-01 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | +500 | $1.87 | $935 | 1,150 |
| 2022-11-22 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | +500 | $1.83 | $915 | 650 |
| 2022-11-21 | Meckler Jeffrey A CEO and Director | Purchase | +9,600 | $1.90 | $18K | 75,374 |
| 2022-11-18 | Meckler Jeffrey A CEO and Director | Purchase | +400 | $1.76 | $705 | 65,774 |
| 2022-09-30 | Karah Hila Director | Grant or award · Stock Option (right to buy) | +13,750 | 13,750 | ||
| 2022-09-30 | Gilbert Mark John Director | Grant or award · Stock Option (right to buy) | +13,750 | 13,750 | ||
| 2022-09-30 | Pomerantz Roger Director | Grant or award · Stock Option (right to buy) | +81,000 | 81,000 | ||
| 2022-09-30 | O'CALLAGHAN BRIAN Director | Grant or award · Stock Option (right to buy) | +13,750 | 13,750 | ||
| 2022-09-30 | MADDALUNA ANTHONY J Director | Grant or award · Stock Option (right to buy) | +13,750 | 13,750 | ||
| 2022-09-30 | Hayes William B Director | Grant or award · Stock Option (right to buy) | +13,750 | 13,750 |
Page 5 of 7 · 127 trades